The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer
The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and d...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/5/939 |
| _version_ | 1797264709010849792 |
|---|---|
| author | Haidar Al Saffar David C. Chen Carlos Delgado Jacob Ingvar Michael S. Hofman Nathan Lawrentschuk Marlon Perera Declan G. Murphy Renu Eapen |
| author_facet | Haidar Al Saffar David C. Chen Carlos Delgado Jacob Ingvar Michael S. Hofman Nathan Lawrentschuk Marlon Perera Declan G. Murphy Renu Eapen |
| author_sort | Haidar Al Saffar |
| collection | DOAJ |
| description | The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA’s expression and its impact on personalised treatment, particularly the use of [<sup>177</sup>Lu] Lu-PSMA-617 radioligand therapy. This review emphasises the essential role of PSMA PET/CT in enhancing treatment approaches, improving patient outcomes, and reducing unnecessary interventions, positioning it as a key element in personalised PCa management. |
| first_indexed | 2024-04-25T00:33:12Z |
| format | Article |
| id | doaj.art-40aec91725c7462c8220163bbe92e048 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-04-25T00:33:12Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-40aec91725c7462c8220163bbe92e0482024-03-12T16:40:55ZengMDPI AGCancers2072-66942024-02-0116593910.3390/cancers16050939The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate CancerHaidar Al Saffar0David C. Chen1Carlos Delgado2Jacob Ingvar3Michael S. Hofman4Nathan Lawrentschuk5Marlon Perera6Declan G. Murphy7Renu Eapen8Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, AustraliaDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, AustraliaSchool of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey 64849, MexicoDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, AustraliaProstate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, AustraliaDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, AustraliaDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, AustraliaDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, AustraliaDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, AustraliaThe review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA’s expression and its impact on personalised treatment, particularly the use of [<sup>177</sup>Lu] Lu-PSMA-617 radioligand therapy. This review emphasises the essential role of PSMA PET/CT in enhancing treatment approaches, improving patient outcomes, and reducing unnecessary interventions, positioning it as a key element in personalised PCa management.https://www.mdpi.com/2072-6694/16/5/939prostate-specific membrane antigenPSMA PET/CTaggressive prostate canceruro-oncologybiochemical recurrence |
| spellingShingle | Haidar Al Saffar David C. Chen Carlos Delgado Jacob Ingvar Michael S. Hofman Nathan Lawrentschuk Marlon Perera Declan G. Murphy Renu Eapen The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer Cancers prostate-specific membrane antigen PSMA PET/CT aggressive prostate cancer uro-oncology biochemical recurrence |
| title | The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer |
| title_full | The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer |
| title_fullStr | The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer |
| title_full_unstemmed | The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer |
| title_short | The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer |
| title_sort | current landscape of prostate specific membrane antigen psma imaging biomarkers for aggressive prostate cancer |
| topic | prostate-specific membrane antigen PSMA PET/CT aggressive prostate cancer uro-oncology biochemical recurrence |
| url | https://www.mdpi.com/2072-6694/16/5/939 |
| work_keys_str_mv | AT haidaralsaffar thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT davidcchen thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT carlosdelgado thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT jacobingvar thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT michaelshofman thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT nathanlawrentschuk thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT marlonperera thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT declangmurphy thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT renueapen thecurrentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT haidaralsaffar currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT davidcchen currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT carlosdelgado currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT jacobingvar currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT michaelshofman currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT nathanlawrentschuk currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT marlonperera currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT declangmurphy currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer AT renueapen currentlandscapeofprostatespecificmembraneantigenpsmaimagingbiomarkersforaggressiveprostatecancer |